Expression of Phospholipse C Gamma 2 in Diffuse Large B-Cell Lymphomas,

Minh Q. Huynh(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Jennifer Goßmann(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut)

Blood

November 18, 2011

10.1182/blood.v118.21.3667.3667

Cited by 1

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

|New England Journal of Medicine|2019|1.3k

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

|Journal of Clinical Oncology|2005|573

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

|The Lancet Oncology|2017|493

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

|Leukemia|2012|417